Clara García-Calderón

Clara García-Calderón

Auto-generated profile, based on publicly available information

Clara García-Calderón

Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Junta de Andalucía, Consejo Superior de Investigaciones Científicas), Seville, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Purpose: Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD. Here, we report the results of two phase I/II studies (NCT03415867, GETH-TC; NCT04111497, FHD) that evaluated glasdegib, a smoothened antagonist, as a novel therapeutic agent in refractory scGVHD. Patients and Methods: Adult patients with active scGVHD after ≥1 (FHD) or ≥2 (GETH-TC) lines of therapy were enrolled. Primary endpoints were dose-limiting toxicity (DLT) and MTD in the GETH-TC trial, and safety and tolerability measures in the FHD trial. Glasdegib was administered once daily in 28-day cycles. Responses were scored per 2014 NIH cGVHD criteria. Correlative studies were performed to evaluate the role of fibroblast-independent immune mechanisms on clinical activity. Results: Twenty (GETH-TC) and 15 (FHD) patients were recruited. Treatment-emergent grade (G) ≥2 adverse events (AE) in the GETH-TC trial included muscle cramps (85%), alopecia (50%), and dysgeusia (35%). Two patients experienced a DLT (G3 muscle cramps), and the MTD was established at 50 mg. G3 muscle cramps were the most frequently reported AE (33%) in the FHD trial. At 12-months, the skin/joint scGVHD overall response rate was 65% (all partial responses) in the GETH-TC trial and 47% (6 partial responses, 1 complete response) in the FHD cohort. No immune correlates of response were identified. Conclusions: Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.

29 April 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
MSMaria V. D. Soares
Maria V. D. Soares
VGVirginia Escamilla Gómez
Virginia Escamilla Gómez
RARita I. Azevedo
Rita I. Azevedo
PPPaulo N. G. Pereira
Paulo N. G. Pereira
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
JLJoão F. Lacerda
João F. Lacerda
Chronic graft-versus-host disease (cGVHD) remains a major hurdle to the success of hematopoietic stem cell transplantation, directly affecting patient morbidity and mortality. Impaired regulatory T-cell (Treg) recovery in patients with cGVHD has led to clinical studies aiming to increase peripheral Treg numbers. We conducted phase 1 dose-escalation clinical trials testing the feasibility and safety of using freshly isolated donor-derived Treg infusions in steroid-refractory/dependent cGVHD. The phase 1 was extended to a preliminary phase 2 trial, resulting in a total of 33 treated patients. We report that Treg purification from donor leukapheresis using CliniMACS were feasible and that Treg infusions were safe. Importantly, Treg infusions resulted in improved symptoms, particularly at higher Treg doses. Global responses were observed in 71% of patients, and 52% of patients had at least a 2-point improvement in the cGVHD severity scale. Furthermore, improvement in cGVHD symptoms resulted in reductions in corticosteroids, ruxolitinib, and mycophenolate in 58%, 83%, and 33% of patients, respectively, whereas calcineurin inhibitors were discontinued in 75% of patients. Exploratory analyses revealed the detection of infused Treg clonotypes up to 12 months after infusion and suggest increased Treg numbers in circulation. We observed increases in serum levels of interleukin-7 and interferon gamma and decreases in soluble CD13 and suppression of tumorigenicity 2 over time, which were not statistically significant after adjustment for multiple comparisons. Although these studies were not powered to assess efficacy, they suggest potential therapeutic benefits of donor-derived Treg in cGVHD treatment and highlight the need for larger phase 2 clinical trials. The trials were registered at www.clinicaltrials.gov as #NCT02385019 and #NCT03683498.

25 November 2025
Verified
Other
Open access
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Representativeness of study participants

25 November 2025
Verified
Other
Open access
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n=11 R, n=4 NR) (B), unswitched memory B cells cells (C1D1: n=12 R, n=5 NR; C2D1: n=12 R, n=4 NR; C4D1: n=11 R, n=3 NR) (C) and switched memory B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=4 NR) (D). E) Fold change in CD268 (BAFF) expression on B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=3 NR). MFI normalised ratios were used for expression quantification. MFI, median fluorescence intensity; n.s., non-statistically significant.

25 November 2025
Verified
Other
Open access
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Purpose:Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD. Here, we report the results of two phase I/II studies (NCT03415867, GETH-TC; NCT04111497, FHD) that evaluated glasdegib, a smoothened antagonist, as a novel therapeutic agent in refractory scGVHD.Patients and Methods:Adult patients with active scGVHD after ≥1 (FHD) or ≥2 (GETH-TC) lines of therapy were enrolled. Primary endpoints were dose-limiting toxicity (DLT) and MTD in the GETH-TC trial, and safety and tolerability measures in the FHD trial. Glasdegib was administered once daily in 28-day cycles. Responses were scored per 2014 NIH cGVHD criteria. Correlative studies were performed to evaluate the role of fibroblast-independent immune mechanisms on clinical activity.Results:Twenty (GETH-TC) and 15 (FHD) patients were recruited. Treatment-emergent grade (G) ≥2 adverse events (AE) in the GETH-TC trial included muscle cramps (85%), alopecia (50%), and dysgeusia (35%). Two patients experienced a DLT (G3 muscle cramps), and the MTD was established at 50 mg. G3 muscle cramps were the most frequently reported AE (33%) in the FHD trial. At 12-months, the skin/joint scGVHD overall response rate was 65% (all partial responses) in the GETH-TC trial and 47% (6 partial responses, 1 complete response) in the FHD cohort. No immune correlates of response were identified.Conclusions:Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.

25 November 2025
Verified
Other
Open access
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubation with ionomycin (0.91 µg/mL) and PMA (20 µg/mL). Brefeldin A (10 μg/mL) was added in both conditions. Differences between serial evaluations on day 1 of cycles 1, 2 and 4 were examined in skin/joints scGVHD responder (C1D1: n=11; C2D1: n=13; C4D1: n=12) and non-responder patients (C1D1: n=7; C2D1: n=7; C4D1: n=5). n.s., non-statistically significant. *Omnibus Friedman test. In post-hoc tests, only a statistically significant difference between visits C2D1 and C4D1 was detected (p=0.011).